SCHEMBL26100334

SCHEMBL26100334

O=C1CCN(c2cc(C(=O)N3CCC4(CC3)CNC4)ccc2Cl)C(=O)N1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NAMPT P43490 2/20 0.41
▸ HPGD P15428 1/20 0.40
▸ ENPP2 Q13822 1/20 0.39
▸ ATXN2 Q99700 1/20 0.39
▸ GABRD O14764 2/20 0.39
▸ GABRA1 P14867 2/20 0.39
▸ GABRB1 P18505 2/20 0.39
▸ GABRA5 P31644 2/20 0.39
▸ GABRA3 P34903 2/20 0.39
▸ GABRA2 P47869 2/20 0.39
▸ GABRB2 P47870 2/20 0.39
▸ GABRA4 P48169 2/20 0.39
▸ PKM P14618 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ L3MBTL3 Q96JM7 1/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ CRBN Q96SW2 2/20 0.38
▸ MGLL Q99685 1/20 0.38
▸ POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL30392394 0.94 DDR1 (0.40) NAMPTHPGDENPP2ATXN2
SCHEMBL25596266 0.90 GABRD (0.51) NAMPTGABRDGABRA1GABRB1GABRA5
SCHEMBL30014379 0.90 GABRD (0.51) NAMPTGABRDGABRA1GABRB1GABRA5
Hydrochloric Acid SCHEMBL30864123 0.89 GABRD (0.50) NAMPTGABRDGABRA1GABRB1GABRA5
SCHEMBL30014819 0.89 HPGD (0.43) HPGDENPP2ATXN2GABRDGABRA1
SCHEMBL25920215 0.88 MAPK1 (0.48) HPGDENPP2ATXN2GABRDGABRA1
SCHEMBL30392608 0.86 HPGD (0.44) HPGDPKMKMT2ACRBN
SCHEMBL30267288 0.86 GABRD (0.41) HPGDENPP2ATXN2GABRDGABRA1
SCHEMBL30020819 0.85 HPGD (0.55) HPGDPKMKMT2AL3MBTL1CRBN
Trifluoroacetic Acid SCHEMBL31161877 0.85 GABRD (0.46) NAMPTGABRDGABRA1GABRB1GABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 — — US disclosed
US-20250051338-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-02-13 — — US disclosed
CN-119013277-A TYK2 degrading agent and application thereof 凯麦拉医疗公司 2024-11-22 — — CN disclosed
WO-2024220937-A2 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2024-10-24 — — WO disclosed
EP-4423086-A1 TYK2 DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-09-04 — — EP disclosed
WO-2023076161-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, CSNK2A1, CSNK2A2 NAMPT 3455/4885HPGD 3257/4885ENPP2 3024/4885
US-20250051338-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, DYRK2, DYRK1A NAMPT 3269/4885HPGD 4054/4885ENPP2 822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback